Marijuana in Michigan: What You Need to Know

Marijuana in Michigan: What You Need to Know

[Canniseur: While I’m exceedingly happy to see Michigan to be a focus of this article, I wish CFN had used authors who knew the state at least well enough to spell the name of a particular city correctly. Heck, his editor didn’t catch it either! The author only lists dispensaries in two cities. And one of the dispensaries he listed is not in business.]

While recreational marijuana use legalized in Michigan in 2018, legal frameworks are not expected to be complete until 2020. The state has had a medical marijuana landscape in place since 2008 however, so a thriving dispensary scene is already in place. In this article, we will look at the prevalence of cannabis use in Michigan and its potential future market, the laws governing use and possession, the impact of legalization there on the Midwest region, and then round up a partial list of current dispensaries and resources.

The Michigan Marijuana Market

When adult recreational use passed in Michigan, the law gave local jurisdictions the choice over whether they want the legal cannabis industry to operate in their town or not. More than 130 different local communities have passed ordinances that allow medical marijuana businesses to operate in Michigan, meaning a robust market is already established. Although more than 400 cities opted out or have not established the legality of cannabis, most people in Michigan are located close enough to a legalized municipality to make purchasing cannabis products easy.

According to the Lansing Business Review, Michigan has the potential to become the third largest medical marijuana market in the country, behind California and Colorado. In 2018, nearly 250,000 medical marijuana patients were registered in the state, and with adult recreational use now legalized the number of consumers is expected to fly through the roof. Regulated recreational stores are expected to open in 2020.

Medical Marijuana Laws in Michigan

The Michigan Compassionate Care Initiative was passed in 2008, making it the 13th state to legalize cannabis in the USA. While adult recreational use was decriminalized in 2018, many towns already had decriminalization laws on the books. The university town of Anne Arbor passed an ordinance in 1972 for example, which made them a pioneer of marijuana legalization not just in the United States but around the world. This has greatly contributed to the later legalization pushes and the widespread cannabis culture that is active in Michigan at the present.

Personal possession and cultivation are now legal for all adults over the age of 21 in Michigan, which is the second most populous state to have passed adult recreational use laws. Possession is limited to 2.5 ounces and cultivation is limited to 12 plants although up to 10 ounces may be possessed by each individual if it is stored under lock and key. Marijuana is also an approved medicinal substance for over two dozen different qualifying conditions and patients can receive herb from a qualified caregiver.

The Impact of Michigan’s Legalization on the Midwest Region

Michigan is the first state in the MidWest region to legalize marijuana for adult recreational use, meaning that it will affect the entire area. Also the most populous state in the Midwest, Michigan stands to become a model for marijuana legalization and pave the way for other states to pass similar legislation, according to a recent article in High Times Magazine. In the meantime, consumers from other MidWest states in order to purchase cannabis products legally, which will be an economic boon to the cannabis economy.

States like Illinois and Missouri already have medicinal marijuana programs in place, and the passage of recreational use in Michigan will surely encourage them and others to follow suit. The entire midwest is expected to be a major player in the multi-billion dollar cannabis industry with sales in Michigan alone projected to reach nearly 900 million dollars by 2015. Illinois recently passed a groundbreaking “Opioids Bill” which allows patients to trade in their opioid-based medications for cannabis instead. If and when this program is extended across the Midwest region daily cannabis use will become a norm for millions of people.

Medical Marijuana Dispensaries in Michigan

Adult recreational vendors are projected to open in 2020, but right now these are just some of the medicinal marijuana dispensaries that have been in operation since the Compassionate Care Initiative was passed in 2008. Here is a partial list of dispensaries found in the two main markets, Detroit and Anne Arbor, taken from, visit them for a complete list of all dispensaries in Michigan.


420 Dank

11999 Gratiot Ave Detroit, MI 48213(313) 284-3063

5 & Dime

20561 Dwyer St Detroit, MI 48234(313) 733-6006


19709 W Seven Mile Rd Detroit, MI 48219(313) 766-5662

BotaniQ Detroit

2540 Rosa Parks Blvd Detroit, MI 48216(313) 450-1400

Chronic Releaf

21651 W Eight Mile Rd Detroit, MI 48219(313) 693-4564

Corktown Collective

2101 W Lafayette Blvd Ste 106 Detroit, MI 48216(313) 265-3740

Far West Holistic Center

21221 8 Mile Rd Detroit, MI 48219(313) 977-9911

Green Cross

14239 Eight Mile Rd Detroit, MI 48219(888) 420-2790

Green Door Alternative

7304 Michigan Ave Detroit, MI 48210(313) 254-9468

Green Genie

24600 W McNichols Rd Detroit, MI 48219(313) 977-9027

Healing Tree Wellness Center

15308 Eight Mile Rd Detroit, MI 48205(313) 466-3366

House of Dank

3340 Eight Mile Rd Detroit, MI 48234(313) 305-4040

King SeaWeed

3600 E Eight Mile Rd Detroit, MI 48234(313) 733-4158

Michigan Medical

14917 Gratiot Ave Ste B Detroit, MI 48205(313) 264-1999

Motor City Kush Detroit

10 E 8 Mile Rd Detroit, MI 48203(313) 707-0903

Motown Meds

18334 W Warren Ave Detroit, MI 48228(313) 914-2319

Nature’s Alternative

15837 Mack Ave Detroit, MI 48224(313) 885-0000

Plan B Wellness Center

20101 W Eight Mile Rd Detroit, MI 48219(248) 470-4638

THC Detroit

19533 W Warren Ave Detroit, MI 48228(313) 266-7738

The Green Mile Detroit

6650 E Eight Mile Rd Detroit, MI 48234(313) 826-1479

The House of Mary Jane

19154 James Couzens Fwy Detroit, MI 48235(313) 340-9202

Utopia Gardens

6541 E Lafayette St Detroit, MI 48207(313) 332-0544

Anne Arbor

Ann Arbor Health Patient Collective

3060 Packard St Ann Arbor, MI 48108(734) 929-5645

Arbors Wellness

321 E Liberty St Ann Arbor, MI 48104(734) 929-2602


1818 Packard St Ann Arbor, MI 48104(734) 213-1420

Bloom City Club

423 Miller Ave Ann Arbor, MI 48103(734) 585-0621

Exclusive Provisioning Center

3820 Varsity Dr Ann Arbor, MI 48108(734) 494-0772

Green Planet

700 Tappan Ave
Ann Arbor, MI 48104
(734) 845-2172

Liv Wellness

603 E William St
Ann Arbor, MI 48104
(734) 780-7018

Medicine Man of Ann Arbor

2793 Plymouth Rd Ste K
Ann Arbor, MI 48104
(734) 800-4194

Om of Medicine

112 S Main St
Ann Arbor, MI 48104
(734) 369-8255

People’s Choice Alternative Medicine

2245 W Liberty St
Ann Arbor, MI 48103
(734) 369-8573

Treecity Health Collective

2730 Jackson Ave

Ann Arbor, MI 48103

(734) 369-3212

Marijuana Advocacy Organizations and Resources in Michigan

Michigan NORML –

Americans for Safe Access, Michigan Chapter –

The Detroit Free Press Marijuana Coverage –

Original Post: CFN Media Group: Marijuana in Michigan: What You Need to Know

Grown Rogue Launches 3.5oz Nitrogen Sealed Cannabis Glass Jars to Guarantee Freshness

Grown Rogue Launches 3.5oz Nitrogen Sealed Cannabis Glass Jars to Guarantee Freshness

Ed. Note: Grown Rogue continues its innovative streak with nitrogen sealed glass jars. They are also crowdsourcing the effects of their strains. This is a company to keep an eye on for their very cool innovations.

MEDFORD, OR, Dec. 3, 2018 /CNW/ – Grown Rogue International Inc. (CSE:GRIN) (“Grown Rogue” or the “Company“), announces the latest addition to its experience-branded cannabis product line, with the launch of 3.5oz nitrogen sealed flower jars.

Following the success of Grown Rogue’s patent-pending nitrogen sealed pre-rolls, Grown Rogue now introduces 3.5oz flower jars that are nitrogen sealed guaranteeing fresh connoisseur quality premium cannabis.

Highest quality THC CBD cannabis marijuana flower buds nitrogen-sealed in glass jars (CNW Group/Grown Rogue)

The premium nitrogen fresh-sealed flower glass jars are an industry first and produce a noticeable “woosh” sound when opened. “It’s like opening a fresh can of vacuum-sealed coffee,” said Obie Strickler, CEO of Grown Rogue. This guarantees freshness through the sealing process. “In keeping with our premium product line of products including oils and concentrates, our nitrogen-sealed flower jars are classified by experience,” Strickler added. “In addition, unlike canned packing, glass packaging gives our customers the ability to view and confirm the premium signature product before purchasing.”

Grown Rogue is the only vertically integrated cannabis company that crowdsources consumer experiences from users of its products to categorize cannabis strains by the resulting effect, to ensure the Right Experience, Every Time.™ The Company introduced the ROGUE Study in late 2017 to crowdsource survey information from customers to categorize the experience or effect of the many diverse strains. The survey, designed by PhD. Research Psychologists at the University of California – Santa Barbara, uses scientifically validated questions to capture the physiological and psychological effects of a cannabis consumption.

“Rather than conduct internal testing to determine experience-based classification, we believe the most transparent and accurate representation of cannabis experiences has to come from crowd consensus of real time users, so we created the ROGUE Study to crowdsource the data,” said Mr. Strickler.

Headquartered in Oregon’s Rogue Valley, known for its premier cannabis growing microclimates, the Company operates approximately 90,000 SQ FT of cultivation through both outdoor and best in class indoor facilities. The Company’s Chief Strategy Officer, Jacques Habra, explained “There has been limited group testing on the actual user experience around the varying cannabis strains.  Rather than rely on anecdotes or wait for academia or government agencies to conduct testing, we took a forward thinking approach to capture people’s experiences in a qualified, meaningful way from the very users of the product.”

About Grown Rogue

Grown Rogue International (CSE: GRIN) is a vertically-integrated, multi-state Cannabis brand specializing in “seed to experience” products through an experienced management team, state of the art indoor and outdoor manufacturing facilities, and a proprietary distribution platform featuring exclusive partnership with Microsoft 365. Grown Rogue’s diverse product suite includes premium flower, patent-pending nitrogen sealed pre-rolls, 3.5 oz flower jars, oil and concentrate distillates, and most recently dark chocolate edibles featuring partnership with world-renowned chocolatier.

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company, and (iv) expectations for other economic, business, and/or competitive factors.  Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: the potential impact of the announcement of the going public transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; and increasing costs of compliance with extensive government regulation, and other risks described in the Company’s Listing Statement available on

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

Safe Harbor Statement:
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the Company’s Form 20-F and 6-K filings with the Securities and Exchange Commission.


The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:

The post Grown Rogue Launches 3.5oz Nitrogen Sealed Cannabis Glass Jars to Guarantee Freshness appeared first on CannabisFN.

Original Post: CFN Media Group: Grown Rogue Launches 3.5oz Nitrogen Sealed Cannabis Glass Jars to Guarantee Freshness

Another Alcohol Giant Looks to Enter Cannabis Industry

Another Alcohol Giant Looks to Enter Cannabis Industry

Ed. Note: Not surprising. And Diageo has its roots in the prohibition of alcohol in the US. Diagio bought several of the brands once marketed by Seagrams. Seagrams was owned by the Bronfman family and during the 1920s and early 30s was one of the biggest exporters (from Canada) of the Seagrams brands. From one prohibition to another!

Diageo plc (NYSE: DEO), the maker of Guinness beer and Crown Royal Canadian whiskey, is actively pursuing a deal with a Canadian cannabis firm, according to BNN Bloomberg, which cited multiple sources familiar with the matter.

The company has held serious discussions with at least three major licensed producers over the past month to determine their interest in a potential investment or collaboration to produce cannabis-infused beverages. A senior executive team also attended a marijuana conference in Toronto last week to discuss possible partnerships or an equity arrangement.

The cannabis industry is projected to generate upwards of $75 billion in global sales by 2030, according to Cowen & Co., driven by the legalization of adult-use cannabis across Canada and many U.S. states. There’s also evidence that cannabis legalization has led to a decrease in binge drinking, which suggests that it could be cannibalizing alcohol sales.

Molson Coors Brewing Co. (NYSE: TAP) and Constellation Brands Inc. (NYSE: STZ) have already announced major moves into the cannabis space over the past couple years. Molson Coors formed a joint venture with The Hydropothecary Corporation (TSX-V: THCX) while Constellation Brands recently increased its investment in Canopy Growth Corp. (NYSE: CGC) to nearly 40 percent.

Many analysts believe that alcoholic beverage companies are interested in the cannabis space as a way to diversify into an area that might cannibalize its core sales. With Canada legalizing adult-use cannabis later this year, these companies could be planning a major move into the market with cannabis-infused drinks designed to supplement their alcohol offerings.

The entry into the U.S. and other global markets is less certain. With cannabis illegal on a federal level, it’s unlikely that multinational beverage companies would introduce products until a federal framework for legalization is introduced. The upshot is that may be happening relatively soon as a growing number of U.S. states and countries liberalize their laws.

The post Another Alcohol Giant Looks to Enter Cannabis Industry appeared first on CannabisFN.

Original Post: CFN Media Group: Another Alcohol Giant Looks to Enter Cannabis Industry

Acreage Holdings Closes Largest Private Placement in Cannabis History

Acreage Holdings Closes Largest Private Placement in Cannabis History

Acreage Holdings (“Acreage”), one of the United States’ largest vertically integrated multi-state cannabis operators, announced it has successfully closed its Series E funding round. The Company secured $119 million of capital and concurrently completed the rollup of control positions in several U.S. states. The proceeds raised will be used to prepare the company for its impending public listing.

“The response we received from our investor partners was profoundly encouraging. The combination of monies raised and the rollup cements Acreage as one of the best capitalized companies in the industry with a footprint that is second to none,” Kevin Murphy, founder and CEO of Acreage Holdings said. “This gives us an exceptionally strong investment proposition to bring into the public markets in our upcoming listing.”

It is believed that the $119 million raised represents the largest private funding raise in U.S. cannabis history. Acreage currently owns or operates licenses in 13 states and plans to use the monies raised to acquire additional licenses, brands and other properties to increase its reach, breadth of offerings and depth of management team. Acreage intends to list the Company this fall on the Canadian Securities Exchange (the “CSE”).

“We are planning on listing on the CSE for many reasons, including the positive reception that the Canadian institutional investment community has shown to the U.S. cannabis industry and to Acreage in particular. Additionally, the CSE has become the exchange of choice for U.S. companies like ours,” Murphy continued. “The liquidity on the CSE is incredibly attractive to Acreage, and we know that retail investors in the U.S. have become comfortable with that exchange. We expect to see a tremendous response to our offering this fall.”

“Our objective with our investors is to set the standard in terms of professionalism and competency in order to remove as much risk from cannabis investing as possible,” said George Allen, the President of Acreage Holdings. “It is a mission that will remain paramount to us as we transition from a private to a public investor base.”

Acreage Holdings is a vertically integrated, multi-state owner of cannabis licenses and assets in states where either medical and/or adult use of cannabis is legal. Headquartered in New York City and currently operating in 13 states, Acreage owns cultivation, processing and dispensary operations and has one of the largest footprints of any cannabis company in the U.S. Acreage is dedicated to building and scaling operations to create a seamless, consumer-focused branded cannabis experience.

The post Acreage Holdings Closes Largest Private Placement in Cannabis History appeared first on CannabisFN.

Original Post: CFN Media Group: Acreage Holdings Closes Largest Private Placement in Cannabis History

Cannabinoids May Do More Than Manage Cancer Symptoms

Cannabinoids May Do More Than Manage Cancer Symptoms

The liberalization of cannabis laws around the world has opened the door for researchers to explore the therapeutic benefits of cannabinoids. While GW Pharmaceuticals plc (NASDAQ: GWPH) has already launched products targeting epilepsy and spasticity in Multiple Sclerosis, emerging research suggests that they could play a role in treating many types of cancers.

In this article, we will look at how cannabinoids are currently being used by physicians and how companies, such as Pascal Biosciences Inc. (TSX-V: PAS), are exploring new treatment options and combination therapies.

Pain & Appetite Stimulation

Cannabinoids have been primarily used by physicians to treat the side-effects of cancer. For example, cannabinoids have a well known anti-inflammatory effect that helps reduce pain, while animal studies have strongly suggested that tetrahydrocannabinol (THC) and other cannabinoids can help stimulate appetite and prevent vomiting caused by certain types of chemotherapy.

The most common cancer-related indications with approved drugs around the world include:

  • Stimulating appetite.
  • Pain relief.
  • Nausea and vomiting.
  • Anxiety and sleep.

Dronabinol and Nabilone were both approved by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-related nausea and vomiting in patients that have not responded to conventional therapies. These drugs were possible because they are synthetic cannabinoids created in a lab rather than natural cannabinoids isolated directly from the cannabis plant.

Potential Anticancer Activity

Researchers have been actively studying cannabinoids to see if they could be beneficial in the treatment of cancer rather than just its side effects.

Cannabinoids have numerous possible effects that could play a role in cancer treatment, according to

  • Anti-inflammatory activity.
  • Blocking cell growth.
  • Preventing the growth of blood vessels that supply tumors.
  • Antiviral activity.

There are more than 3,000 studies published on Google Scholar in 2018 alone, with many more that have been published in prior years. These studies address everything from treating cancer symptoms to destroying cancer cells by exposing them to cannabinoid compounds.

Research in the United States has been hindered by the requirement for any researchers interested in studying the drug to obtain a Schedule I license from the Drug Enforcement Administration (DEA) and approval from the National Institute on Drug Abuse (NIDA). However, there are a growing number of scientists in other jurisdictions with more favorable laws, including Canada, where medical cannabis is federally legal.

In June, the company announced that it received a license from the U.S. DEA to conduct research and development on cannabinoids. As one of a few organizations with a Schedule I researcher license, the company is positioning itself to become a leader in cannabinoid drug development. The company also renewed its UBC collaboration and continues to financially support Dr. Wilfred Jefferies’ laboratory at the Michael Smith Laboratories.

Immunotherapy Possibilities

Pascal Biosciences Inc. (TSX-V: PAS) believes that cannabinoids could also play a role in helping existing immunotherapy drugs better target cancer cells. In February, the company announced the discovery of certain cannabinoids that enhanced the immunogenicity of tumor cells, which rendered them more susceptible to recognition by the immune system. The discovery is important because it can be used with a new class of cancer fighting agents — known as checkpoint inhibitors.

“We are very excited about this novel discovery,” commented Dr. Patrick Gray, CEO of Pascal Biosciences. “Cannabinoids typically have good pharmacological properties, as most have low toxicity and are easily absorbed into the blood, which are great advantages for drug development. We have tested hundreds of natural and synthetic cannabinoids in our proprietary assay. This will enable us to soon determine an optimal product. In combination with immune checkpoint inhibitors, cannabinoids may significantly improve cancer care. We look forward to soon translating our results into clinical studies.”

Looking Ahead

Pascal Biosciences Inc. (TSX-V: PAS) represents a unique investment opportunity in the cancer treatment space. After making its discovery and obtaining a DEA license, the company is well positioned to advance its research programs and ultimately generate long-term value for shareholders. Last week, Pascal appointed Julie Eastland, an accomplished financial executive, to the Board of Directors. Ms. Eastland is a seasoned strategic and financial executive with more than 25 years of experience in public and private biotechnology companies. “Ms. Eastland has strong relationships with investors, investment bankers and analysts covering the U.S. public biotech sector, and excellent experience in partnering, acquisitions, collaborations, and licensing. She will work closely with Pascal to align our scientific strategy with our financial goals,” stated Dr. Patrick Gray, CEO of Pascal.
For more information, visit the company’s website at


The above article is sponsored content. Emerging Growth LLC, which owns and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:

The post Cannabinoids May Do More Than Manage Cancer Symptoms appeared first on CannabisFN.

Original Post: CFN Media Group: Cannabinoids May Do More Than Manage Cancer Symptoms

Cannabis News Highlights
Get Free Weekly News

Subscribe and get the best cannabis news of the week delivered directly to you.

Thank you for subscribing.

Something went wrong.